Table 5.

Summary of TEAEs (incidence >10%) for system organ class by treatment

	Sandoz proposed biosimilar pegfilgrastim N = 176, n (%)	Reference pegfilgrastim N = 178, n (%)
Total number of subjects with at least one TEAE	170 (97)	172 (97)
Musculoskeletal and connective tissue disorders	163 (93)	161 (90)
Nervous system disorders	107 (61)	109 (61)
General disorders and administration site conditions	79 (45)	75 (42)
Gastrointestinal disorders	39 (22)	44 (25)
Infections and infestations	19 (11)	21 (12)
Respiratory, thoracic and mediastinal disorders	16 (9)	19 (11)

N, number of subjects in treatment group; n, number of subjects with event; TEAE, treatment‐emergent adverse event